Pharmacy

Rare kidney disease

340B bills and regulations

Updated FDA regulation around the use of Testosterone

Prescription drug industry issues relating to domestic construction and maintenance employment and all other issues affecting employment in the industry, generally.

Access to PDTs Act - Medicare/Medicaid coverage of prescription digital therapeutics Medicaid VBPs for Patients Act - Codifying Medicaid Multiple Best Price Rule Ensuring Access to Pharmacist Services Act - Medicare Part B payment for certain pharmacist-administered services General support for Medicaid funding

340B

S.527Prescription Pricing for the People Act of 2025To require the Federal Trade Commission to study the role of intermediaries in the pharmaceutical supply chain and provide Congress with appropriate policy recommendations, and for other purposes. S.1040Drug Competition Enhancement ActTo amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. S.1041Affordable Prescriptions for Patients ActTo amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1097Interagency Patent Coordination and Improvement Act of 2025To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes. S.1095Stop STALLING ActTo enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes. S.1096Preserve Access to Affordadable Generics and BiosimilarsTo prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products S.2276/3269ETHIC ActTo address patent thickets. S3014 Ensuring Timely Access to Generics Act of 2025To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions. S1954Biosimilar Red Tape Elimination ActTo improve the requirements for making a determination of interchangeability of a biological product and its reference product.

Issues realted to the 340B prescription drug program; Appropriations